Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Editorial] Dolutegravir for HIV: a lesson in pregnancy safety research

Preliminary results prompted WHO, the European Medicines Agency, and the US Food and Drug Administration to issue warnings on May 18 about the use of dolutegravir, a first-line antiretroviral drug, by women at the time of conception. In an unplanned preliminary analysis of an ongoing 4-year observational study in Botswana, 0·9% (4/426) of babies whose mothers became pregnant while taking dolutegravir had a neural tube defect compared with 0·1% (14/11 173) of babies whose mothers took other HIV medicines.